Participated · Series F · Apr 2026

Calyxo develops the CVAC System, an all-in-one aspiration-based platform that uses irrigation and vacuum aspiration to continuously clear kidney stone fragments during and after laser lithotripsy. The CVAC System was FDA-cleared in 2024 and aims to enable more complete stone clearance, which the company says drives improved clinical outcomes. Clinical, preclinical, and health economic evidence cited by Calyxo report low residual stone volume, improved procedural efficiency, and reductions in downstream healthcare utilization and cost. The company announced that over 40,000 patients have been treated with the CVAC System, signaling growing physician adoption. Calyxo plans to use newly raised capital to expand commercial infrastructure, generate further clinical and health-economic evidence through ongoing and future studies, and continue product innovation. The company describes itself as focused on paradigm-shifting solutions to improve kidney stone care.

Participated · Equity · Sep 2024

Zing Health offers managed-care Medicare Advantage plans that include supplemental benefits and access to a broad network of provider partners. Each member receives personalized care tailored to health conditions and social needs, enabled by product design, technology, and value-based care delivery. The company emphasizes integrated plans focused on chronic special needs. Zing Health intends to use the new proceeds to expand those integrated, chronic special needs focused plans to more beneficiaries and to further integrate its member experience with high-quality care providers. The business is led by CEO Andrew Clifton and was co-founded in 2019 by Dr. Eric Whitaker and Garfield Collins alongside Health 2047. The company is based in Chicago, Illinois.

Led · Convertible Note · Feb 2024

T2 Biosystems develops rapid sepsis-detection diagnostics based on its proprietary T2MR technology. The company markets a product lineup and says it has a promising pipeline aimed at improving patient care and reducing healthcare costs. T2 Biosystems was founded in 2006 and is located in Lexington, Massachusetts, with 51–200 employees. Financially, the company has raised $133M to date. Recently it agreed to convert $15M of debt into equity with CRG to bolster its financial standing, a move pending shareholder approval. Management framed the transaction as part of ongoing strategic amendments to the CRG term loan and expressed gratitude for CRG's continued support. T2 Biosystems builds and commercializes the T2MR® magnetic biosensor platform and its flagship T2Candida molecular diagnostic panel to detect species-specific Candida directly from whole blood. The T2MR technology uses miniaturized magnetic resonance to detect molecular, immunoassay, or hemostasis targets from complex clinical samples including blood, sputum and urine. T2Candida delivers results in approximately three hours, with sensitivity reported as low as 1 CFU/mL and diagnostic speed up to 25 times faster than current blood-culture methods. The company intends to use proceeds from its latest financing to support clinical programs and commercialization of T2Candida, complete development of additional sepsis diagnostic panels, and advance R&D of other molecular, immunodiagnostic and hemostasis assays. The platform targets faster identification of candidemia and sepsis, conditions the article notes are major causes of hospital-acquired infection and mortality where earlier detection can substantially reduce deaths. T2 Biosystems completed a $40 million financing to fund these clinical and commercialization efforts. T2 Biosystems develops and commercializes a magnetic resonance (T2MR) diagnostic platform and the T2Dx benchtop instrument that directly analyzes unprocessed clinical samples. Its lead product is the T2Candida assay, a rapid multiplexed test for five Candida species intended to detect bloodstream infections and sepsis in under two hours. The company says T2MR eliminates the need for sample purification and blood culture growth, providing sensitive and rapid results in less than two hours. T2 Biosystems planned a beta launch of the T2Dx instrument in the fall and expected an FDA submission for the T2Candida panel in the second half of 2012. The firm aims to expand its pipeline into additional diagnostic tests focused on sepsis, infectious disease, therapeutic drug monitoring and coagulation. The newly announced financing will support ongoing development and clinical trials, regulatory approval and commercialization efforts, and expansion of the company’s partnering program. T2 Biosystems is a Cambridge, MA–based biotechnology company focused on a diagnostic platform that combines nanotechnology with the miniaturization of magnetic resonance to perform molecular and immunoassay diagnostics on a small bench-top instrument. The company aims to eliminate extensive sample preparation and enable rapid testing in decentralized settings such as hospitals, diagnostic laboratories and medical offices. T2 intends to build a pipeline of products around this proprietary technology to improve disease diagnosis and treatment. The new funding is earmarked to accelerate development and commercialization of an initial menu of diagnostic tests for those decentralized settings. Leadership emphasizes a mission to revolutionize diagnostic testing, improve patient care, and reduce healthcare costs by enabling immediate, accurate testing in nearly any setting. The company previously raised $10.8M in a Series B in 2008. T2 Biosystems is a Cambridge, Mass.-based company developing diagnostic devices that combine MRI properties and nanotechnology. The company plans to use the new funding to develop a beta version of that device. It intends to run the beta through a series of tests over the next 18 months. T2 currently has 20 employees. Financially, it recently received $10.8M in a second-round financing and previously raised $5.5M in a first round in 2006. The new capital is targeted at product development and testing.

Led · Debt Financing · May 2019

Aerin Medical is a privately held, venture-backed medical device company headquartered in Mountain View, California, focused on expanding access to relief for patients with chronic ENT conditions. Its products VivAer® (for nasal airway obstruction) and RhinAer® (for chronic rhinitis) leverage a proprietary temperature-controlled technology as alternatives to invasive surgery. The company reports that more than 150,000 patients have been treated with its products to date. Aerin said it will use recent financing to drive additional commercial expansion, invest in R&D, and further expand its clinical evidence portfolio. Management emphasized plans to deepen penetration in markets for nasal obstruction and chronic rhinitis. Financially, Aerin completed a $32.5 million equity financing and secured a debt facility to refinance existing debt and provide additional financial flexibility. Aerin Medical commercializes non-invasive, temperature-controlled radiofrequency treatments for chronic nasal conditions through its VivAer and RhinAer products. VivAer, launched in the U.S. in 2018, treats nasal airway obstruction (which the company cites as affecting 20 million Americans); RhinAer launched in 2020 for chronic rhinitis. More than 60,000 patients have been treated with Aerin products to date, and the company reported 10 new peer-reviewed clinical publications in the last year. Aerin is privately held and venture-backed, with U.S. offices in California and Texas. The company intends to use new financing to scale commercialization and expand market access to meet physician and patient demand. Aerin Medical develops non-invasive, office-based treatments for chronic nasal airway conditions. Its FDA-cleared VivAer® Stylus treats nasal airway obstruction and the RhinAer® Stylus treats chronic rhinitis using a proprietary temperature-controlled technology. The company provides tissue-sparing solutions for otolaryngologists (ENTs) to improve patient quality of life. Aerin is venture-backed and has offices in Sunnyvale, California and Austin, Texas. The company announced a leadership change with the appointment of Matt Brokaw as President and CEO. Proceeds from the financing will be used to accelerate commercial growth, support new clinical studies, and develop new products. Aerin Medical, led by CEO Fred Dinger and based in Austin, Texas, develops and commercializes minimally invasive treatments for nasal airway disorders. Its flagship product is the Vivaer Nasal Airway Remodeling System, a physician‑office procedure for treating nasal obstruction. The company focuses on improving patients' quality of life through disruptive, office‑based interventions. Financially, Aerin closed a $50M non‑dilutive term loan with CRG LP, receiving $35M at closing and up to $15M more in milestones. Approximately $16.5M of the proceeds were used to retire existing debt. The remaining funds are designated to accelerate sales and marketing reach and to support the launch of its next product. Aerin Medical is a medical device company that has developed a non-invasive treatment platform using low-power radiofrequency energy to remodel nasal soft tissues and address nasal congestion. The platform is designed for use in the physician’s office to treat underlying causes of nasal breathing disorders. Led by CEO Fred Dinger, Aerin operates offices in Austin, Texas; Sunnyvale, California; and Singapore. The company is backed by healthcare investors KCK Group and Targeted Technology. Aerin closed a $15M venture loan facility provided by Horizon Technology Finance Corporation. The company will use the proceeds for general working capital purposes.

Led · Debt Financing · Mar 2019

Harmony Biosciences, LLC was established in October 2017 and is headquartered in Plymouth Meeting, PA. Its lead investigational product is pitolisant, a first-in-class histamine H3 receptor antagonist/inverse agonist developed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. Pitolisant has been marketed in Europe by Bioprojet since EMA approval in 2016, and Harmony’s New Drug Application for pitolisant was accepted by the FDA on February 12, 2019 and granted Priority Review. The drug holds orphan designation, Fast Track designation for EDS and cataplexy, and Breakthrough Therapy designation for cataplexy. Harmony aims to obtain FDA approval and launch pitolisant in the U.S. in 2019. Financially, the company has raised private equity totaling $295 million and recently secured a $200 million debt facility to provide additional working capital to support growth and launch preparations. Harmony Biosciences is a Plymouth Meeting, PA-based biopharmaceutical company in the Paragon Biosciences corporate family focused on providing novel treatments for orphan and rare central nervous system disorders. The company acquired exclusive US rights to develop, register and market pitolisant from Bioprojet SCR and plans to accelerate its development for adults with narcolepsy. Pitolisant is a selective histamine H3-receptor antagonist/inverse agonist developed by Bioprojet and approved in the EU as WAKIX for narcolepsy with and without cataplexy. Harmony raised $270M in equity financing to facilitate the acquisition and support development and registration efforts. With guidance from Paragon and a joint development committee with Bioprojet, Harmony intends to establish an expanded access program in the US in early 2018 and expects to submit a new drug application in the first half of 2018. Led by CEO Bob Repella, Harmony emphasizes research and development in central nervous system disorders and rare conditions.